Gentherm Incorporated(THRM)Earnings, Financials & Key RatiosGentherm Incorporated (THRM) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
while the forward P/E of 13.07 appears attractive, the inconsistent net margin of 1.1% in 2026Q1 and erratic cash conversion cycles warrant a cautious wait-and-see approach.
Gentherm Incorporated (THRM) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Gentherm Incorporated (THRM) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 23, 2026 | $0.84vs $0.53+58.5% | $394Mvs $362M+8.7% |
| Q1 2026 | Feb 19, 2026 | $0.49vs $0.57-14.0% | $383Mvs $372M+2.9% |
| Q4 2025 | Oct 23, 2025 | $0.73vs $0.66+11.5% | $383Mvs $375M+2.2% |
| Q3 2025 | Jul 24, 2025 | $0.54vs $0.59-8.5% | $375Mvs $373M+0.6% |
Recent stock market news and headlines for Gentherm Incorporated (THRM)
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
The Company Announces Shares for Debt Settlements Toronto, Ontario--(Newsfile Corp. - June 23, 2026) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX0) ("Therma" or the "Company"), a developer and investment partner specializing in advanced medical device technologies, is pleased to announce continued sales momentum for its Venowave mobile compression device in the United States, highlighted by additional follow-on orders from Horizon Health USA ("Horizon") and from Gen-X Med. Building on the rapid deployment of previous shipments, Horizon Health USA has placed a new order for 100 Venowave units.
Key metrics vs top competitors for Gentherm Incorporated (THRM)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $34.48 | $1.06B | 57.47 | 2.64% | 1.22% | 2.73% | — | |
| $14.28 | $270.25M | 23.03 | 4.28% | 1.57% | 4.75% | — | |
| $82.69 | $345.54M | 18.05 | 5.08% | 4.31% | 9.68% | — | |
| $139.64 | $4.17B | 21.03 | 6.03% | 8.84% | 13.06% | — | |
| $28.94 | $734.45M | -22.97 | -3.24% | -12.67% | -10.13% | — | |
| $19.20 | $1.51B | -5.66 | -1.04% | 0.4% | 2.78% | — |
Gentherm Incorporated (THRM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Gentherm Incorporated (THRM) SEC filings — annual & quarterly reports (10-K, 10-Q)
Apr 23, 2026·SEC
Mar 25, 2026·SEC
Mar 17, 2026·SEC
Get notified when THRM posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Gentherm Incorporated (THRM) stock FAQ — growth, dividends, profitability & financials explained
Gentherm Incorporated (THRM) reported $1.53B in revenue for fiscal year 2025. This represents a 20636% increase from $7.4M in 1996.
Gentherm Incorporated (THRM) grew revenue by 2.6% over the past year. Growth has been modest.
Yes, Gentherm Incorporated (THRM) is profitable, generating $22.6M in net income for fiscal year 2025 (1.2% net margin).
Gentherm Incorporated (THRM) has a return on equity (ROE) of 2.7%. This is below average, suggesting room for improvement.
Gentherm Incorporated (THRM) generated $78.6M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
